Castle Biosciences Stock Buy Hold or Sell Recommendation
| CSTL Stock | USD 19.29 0.53 2.83% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Castle Biosciences is 'Sell'. The recommendation algorithm takes into account all of Castle Biosciences' available fundamental, technical, and predictive indicators you will find on this site.
Check out Castle Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide. Note, we conduct extensive research on individual companies such as Castle and provide practical buy, sell, or hold advice based on investors' constraints. Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Castle |
Execute Castle Biosciences Buy or Sell Advice
The Castle recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Castle Biosciences. Macroaxis does not own or have any residual interests in Castle Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Castle Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Castle Biosciences Trading Alerts and Improvement Suggestions
| Castle Biosciences generated a negative expected return over the last 90 days | |
| Castle Biosciences has high historical volatility and very poor performance | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Insider Selling Castle Biosciences, Inc. Insider Sells 22,6 Shares of Stock |
Castle Biosciences Returns Distribution Density
The distribution of Castle Biosciences' historical returns is an attempt to chart the uncertainty of Castle Biosciences' future price movements. The chart of the probability distribution of Castle Biosciences daily returns describes the distribution of returns around its average expected value. We use Castle Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Castle Biosciences returns is essential to provide solid investment advice for Castle Biosciences.
| Mean Return | -0.66 | Value At Risk | -6.33 | Potential Upside | 4.51 | Standard Deviation | 3.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Castle Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Castle Stock Institutional Investors
| Shares | Renaissance Technologies Corp | 2024-12-31 | 685 K | Geode Capital Management, Llc | 2024-12-31 | 628.2 K | Millennium Management Llc | 2024-12-31 | 548.8 K | Point72 Asset Management, L.p. | 2024-12-31 | 547.1 K | Palisade Capital Management Llc | 2024-12-31 | 503.4 K | Nuveen Asset Management, Llc | 2024-12-31 | 465.5 K | Goldman Sachs Group Inc | 2024-12-31 | 432.8 K | Bank Of America Corp | 2024-12-31 | 403.6 K | Kornitzer Capital Management Inc | 2024-12-31 | 384 K | Blackrock Inc | 2024-12-31 | 2.9 M | Vanguard Group Inc | 2024-12-31 | 1.8 M |
Castle Biosciences Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (980K) | 327K | (1.7M) | (4.0M) | (193K) | (202.7K) | |
| Investments | (4.7M) | (66.7M) | (166.5M) | (13.0M) | (50.1M) | (52.6M) | |
| Change In Cash | 311.0M | (80.2M) | (206.7M) | (24.1M) | 20.9M | 11.5M | |
| Net Borrowings | 20.9M | (27.4M) | (8K) | (122K) | (109.8K) | (104.3K) | |
| Free Cash Flow | 5.1M | (22.5M) | (47.3M) | (19.2M) | 36.5M | 38.4M | |
| Depreciation | 472K | 3.4M | 10.5M | 12.3M | 16.0M | 16.8M | |
| Other Non Cash Items | 823K | 33.0M | (19.5M) | (4.9M) | (7.0M) | (6.6M) | |
| Capital Expenditures | 4.8M | 3.5M | 5.6M | 13.6M | 28.3M | 29.7M | |
| Net Income | (10.3M) | (31.3M) | (67.1M) | (57.5M) | 18.2M | 19.2M | |
| End Period Cash Flow | 409.9M | 329.6M | 122.9M | 98.8M | 119.7M | 163.0M | |
| Change To Netincome | (589K) | 9.7M | 13.0M | 14.9M | 17.2M | 18.0M |
Castle Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Castle Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Castle Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Castle stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.64 | |
β | Beta against Dow Jones | 0.19 | |
σ | Overall volatility | 3.83 | |
Ir | Information ratio | -0.15 |
Castle Biosciences Volatility Alert
Castle Biosciences exhibits very low volatility with skewness of -1.01 and kurtosis of 4.36. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Castle Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Castle Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Castle Biosciences Fundamentals Vs Peers
Comparing Castle Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Castle Biosciences' direct or indirect competition across all of the common fundamentals between Castle Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Castle Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Castle Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Castle Biosciences to competition |
| Fundamentals | Castle Biosciences | Peer Average |
| Return On Equity | 0.0431 | -0.31 |
| Return On Asset | 0.011 | -0.14 |
| Profit Margin | 0.05 % | (1.27) % |
| Operating Margin | 0.05 % | (5.51) % |
| Current Valuation | 268.14 M | 16.62 B |
| Shares Outstanding | 28.51 M | 571.82 M |
| Shares Owned By Insiders | 3.30 % | 10.09 % |
| Shares Owned By Institutions | 93.90 % | 39.21 % |
| Number Of Shares Shorted | 1.93 M | 4.71 M |
| Price To Earning | 87.86 X | 28.72 X |
| Price To Book | 1.17 X | 9.51 X |
| Price To Sales | 1.66 X | 11.42 X |
| Revenue | 332.07 M | 9.43 B |
| Gross Profit | 271.86 M | 27.38 B |
| EBITDA | 38.14 M | 3.9 B |
| Net Income | 18.25 M | 570.98 M |
| Cash And Equivalents | 273.17 M | 2.7 B |
| Cash Per Share | 10.39 X | 5.01 X |
| Total Debt | 26.34 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 11.08 X | 2.16 X |
| Book Value Per Share | 16.00 X | 1.93 K |
| Cash Flow From Operations | 64.87 M | 971.22 M |
| Short Ratio | 4.57 X | 4.00 X |
| Earnings Per Share | 0.62 X | 3.12 X |
| Target Price | 39.67 | |
| Number Of Employees | 761 | 18.84 K |
| Beta | 0.98 | -0.15 |
| Market Capitalization | 550.04 M | 19.03 B |
| Total Asset | 531.24 M | 29.47 B |
| Retained Earnings | (200.13 M) | 9.33 B |
| Working Capital | 310.76 M | 1.48 B |
| Current Asset | 125.89 M | 9.34 B |
Note: Disposition of 2130 shares by Derek Maetzold of Castle Biosciences at 19.518 subject to Rule 16b-3 [view details]
Castle Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Castle . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Castle Biosciences Buy or Sell Advice
When is the right time to buy or sell Castle Biosciences? Buying financial instruments such as Castle Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Castle Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cars Thematic Idea Now
Cars
Domestic and international companies involved in manufacturing and serving automobiles and trucks. The Cars theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Castle Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.62 | Revenue Per Share | Quarterly Revenue Growth 0.305 | Return On Assets |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.